About Dr. Wang Liwei
Dr. Wang Liwei (王理伟) is a leading oncologist at Huashan Hospital, Fudan University, specializing in pancreatic cancer, biliary tract cancers, and hepatocellular carcinoma. Recognized as one of China's foremost authorities in gastrointestinal oncology, Dr. Wang has dedicated his career to improving outcomes for patients with some of the most challenging malignancies in oncology — cancers that are frequently diagnosed at advanced stages and require highly individualized, multidisciplinary management.
Dr. Wang is known for his expertise in precision medicine approaches to pancreatic and biliary cancers, including molecular profiling-guided treatment selection, BRCA and homologous recombination deficiency (HRD) testing, and access to novel therapeutic agents through clinical trials. His multidisciplinary approach integrates medical oncology with interventional radiology, hepatobiliary surgery, and palliative care to provide comprehensive, patient-centered cancer management.
Hospital Affiliation
Huashan Hospital, Fudan University is consistently ranked among China's top hospitals. Its gastrointestinal oncology program benefits from close collaboration with the hospital's hepatobiliary surgery, interventional radiology, and gastroenterology departments, enabling seamless multidisciplinary management of complex pancreatic and biliary cancers. The department has access to comprehensive molecular profiling including NGS, BRCA testing, MSI/MMR analysis, and NTRK fusion testing — essential tools for identifying actionable targets in these difficult-to-treat cancers.
Clinical Expertise
- Pancreatic cancer — FOLFIRINOX, gemcitabine/nab-paclitaxel; BRCA/HRD-targeted therapy (olaparib); KRAS G12C inhibitors; borderline resectable and locally advanced disease management
- Biliary tract cancers — cholangiocarcinoma (intrahepatic, perihilar, distal); gallbladder cancer; IDH1, FGFR2, BRAF, HER2-targeted therapy; pemigatinib, ivosidenib
- Hepatocellular carcinoma (HCC) — sorafenib, lenvatinib, atezolizumab/bevacizumab, tremelimumab/durvalumab; TACE and systemic therapy coordination
- Neuroendocrine tumors (NETs) — somatostatin analogues, everolimus, sunitinib, PRRT coordination
- Gastric & gastroesophageal cancer — perioperative chemotherapy, HER2-targeted therapy, immunotherapy combinations
- Molecular profiling & precision oncology — NGS-guided treatment selection, tumor mutational burden (TMB), microsatellite instability (MSI), liquid biopsy
- Clinical trial access — phase I–III trials for novel agents in pancreatic, biliary, and hepatic cancers
- Palliative & supportive oncology — pain management, biliary stenting coordination, nutritional support, quality of life optimization
Academic & Research Contributions
Dr. Wang Liwei has authored numerous peer-reviewed publications in leading oncology journals including the Journal of Clinical Oncology, Annals of Oncology, Gut, and Hepatology. His research focuses on the molecular biology of pancreatic and biliary cancers, the identification of novel therapeutic targets, and the optimization of systemic therapy regimens for Chinese patients with gastrointestinal malignancies.
He is an active member of the Chinese Society of Clinical Oncology (CSCO) and has contributed to the development of national clinical guidelines for pancreatic cancer and biliary tract cancers. Dr. Wang has served as principal investigator on multiple multicenter clinical trials and is a regular presenter at ASCO, ESMO, and CSCO annual meetings. His work on FGFR2 fusion-positive cholangiocarcinoma in Chinese patients has been particularly influential, providing real-world data that informs treatment decisions for this molecularly defined subgroup globally.
Why International Patients Choose Dr. Wang Liwei
Pancreatic and biliary cancers are among the most molecularly complex and therapeutically challenging malignancies. International patients seek Dr. Wang's expertise for second opinions on treatment plans, access to clinical trials evaluating novel targeted agents not yet approved in their home countries, and management of cancers that have progressed on standard regimens.
China's large patient volumes in gastrointestinal oncology mean that Dr. Wang and his team encounter rare molecular subtypes — such as FGFR2 fusion-positive cholangiocarcinoma and BRCA-mutant pancreatic cancer — with a frequency that gives them exceptional clinical experience with precision therapy approaches. For patients with these actionable alterations, access to Dr. Wang's expertise can be genuinely practice-changing.
The cost advantage is also significant: comprehensive molecular profiling, targeted therapy, and clinical trial participation at Huashan are available at a fraction of the cost of equivalent care in Western countries, without compromising on drug quality or clinical standards.
What to Expect at Your Consultation
Consultations with Dr. Wang begin with a thorough review of pathology, molecular profiling results, imaging, and prior treatment history. CMCS will arrange certified translation of all records in advance. Where additional molecular testing — including NGS, liquid biopsy, or BRCA germline testing — is needed, this can typically be arranged within 24–48 hours. Dr. Wang will provide a detailed treatment plan including systemic therapy options, clinical trial eligibility, and supportive care recommendations, summarized in English for your home oncologist.
Frequently Asked Questions
My pancreatic cancer has progressed on gemcitabine. Are there other options?
Yes. Dr. Wang will review your molecular profiling results to identify actionable targets, assess clinical trial eligibility, and recommend second-line or later-line options including FOLFIRINOX, BRCA-targeted therapy, or investigational agents.
Does Huashan perform FGFR2 and IDH1 testing for cholangiocarcinoma?
Yes. Comprehensive molecular profiling including FGFR2 fusion, IDH1/2, BRAF, HER2, and MSI testing is available at Huashan, enabling access to targeted therapies for patients with actionable alterations.
Can I participate in a clinical trial at Huashan?
Eligibility depends on your diagnosis, molecular profile, and prior treatment history. CMCS will work with Dr. Wang's team to assess your eligibility during the consultation process.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking oncology care with Dr. Wang Liwei at Huashan Hospital, including priority appointment scheduling, certified medical translation, molecular profiling coordination, and post-consultation follow-up. Contact us at contract@medicalsh.com, or visit medicalsh.com.
댓글 0개